ArticleMarine drugs2020
Functional Characterization of a New GH107 Endo-α-(1,4)-Fucoidanase from the Marine Bacterium
Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- The Origin, Properties, Structure, Catalytic Mechanism, and Applications of Fucoidan-Degrading Enzymes.Marine drugs · 2025Review
- The Discovery of the Fucoidan-Active Endo-1→4-α-L-Fucanase of the GH168 Family, Which Produces Fucoidan Derivatives with Regular Sulfation and Anticoagulant Activity.International journal of molecular sciences · 2023Article
- Structural and functional characterization of the novel endo-α(1,4)-fucoidanase Mef1 from the marine bacterium Muricauda eckloniae.Acta crystallographica. Section D, Structural biology · 2023Article
- Herbivorous Fish Microbiome Adaptations to Sulfated Dietary Polysaccharides.Applied and environmental microbiology · 2023Article
- Purification and Characterization of the Enzyme Fucoidanase fromFoods (Basel, Switzerland) · 2023Article
- Structural and Biochemical Analysis Reveals Catalytic Mechanism of Fucoidan Lyase fromMarine drugs · 2022Article
- Sulfated Galactofucans: An Outstanding Class of Fucoidans with Promising Bioactivities.Marine drugs · 2022Review
- The Endo-α(1,3)-Fucoidanase Mef2 Releases Uniquely Branched Oligosaccharides fromMarine drugs · 2022Article
- Expression and Biochemical Characterization of a Novel Fucoidanase fromFoods (Basel, Switzerland) · 2022Article
- Marine microbial enzymes for the production of algal oligosaccharides and its bioactive potential for application as nutritional supplements.Folia microbiologica · 2022Review
- The Endo-α(1,4) Specific Fucoidanase Fhf2 FromFrontiers in plant science · 2022Article
- A novel thermostable prokaryotic fucoidan active sulfatase PsFucS1 with an unusual quaternary hexameric structure.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Fucoidans from brown macroalgae are sulfated fucose-rich polysaccharides, that have several beneficial biological activities, including anti-inflammatory and anti-tumor effects. Controlled enzymatic depolymerization of the fucoidan backbone can help produce homogeneous, defined fucoidan products for structure-function research and pharmaceutical uses. However, only a few endo-fucoidanases have been described. This article reports the genome-based discovery, recombinant expression in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.